Article Text

Download PDFPDF
Rare case of COVID-19 vaccine-associated intracranial haemorrhage with venous sinus thrombosis
  1. Pujon Purkayastha1,
  2. Charlie Mckechnie1,
  3. Pallavi Kalkur1 and
  4. Marie Scully2
  1. 1Acute Medicine, Southend Hospital, Westcliff-on-Sea, UK
  2. 2Haematology, University College London Hospitals NHS Foundation Trust, London, UK
  1. Correspondence to Dr Pujon Purkayastha; dr.purkayastha{at}doctors.org.uk

Abstract

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a relatively novel term which describes patients who have developed a low platelet count and prothrombotic tendencies secondary to receiving a vaccine. The concept has been derived from the well-established phenomenon of heparin-induced thrombocytopenia, and several cases of VITT have now been reported in patients who have received the AstraZeneca (ChAdOx1 nCov-19) vaccine. Unfortunately, some of these patients have gone on to develop intracranial venous sinus thrombosis. We present a case of VITT-associated sinus thrombosis secondary to the AstraZeneca (ChAdOx1 nCov-19) vaccine, which was complicated by a large intracerebral haemorrhage.

  • COVID-19
  • haematology (drugs and medicines)
  • immunological products and vaccines
  • global health
  • neuroimaging

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors PP is the primary author of this case study. CM contributed significantly to the case study and was responsible for obtaining patient consent. PK was the haematology consultant in charge of the patient’s care at Southend Hospital. MS provided valuable contributions to the overall management of the patient.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.